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ABSTRACT Cystic fibrosis (CF) is a recessive genetic disease that is characterised by airway mucus
plugging and reduced mucus clearance. There are currently alternative hypotheses that attempt to describe
the abnormally viscous and elastic mucus that is a hallmark of CF airways disease, including: 1) loss of CF
transmembrane regulator (CFTR)-dependent airway surface volume (water) secretion, producing mucus
hyperconcentration-dependent increased viscosity, and 2) impaired bicarbonate secretion by CFTR,
producing acidification of airway surfaces and increased mucus viscosity.
A series of experiments was conducted to determine the contributions of mucus concentration versus
pH to the rheological properties of airway mucus across length scales from the nanoscopic to macroscopic.
For length scales greater than the nanoscopic, i.e. those relevant to mucociliary clearance, the effect of
mucus concentration dominated over the effect of airway acidification.
Mucus hydration and chemical reduction of disulfide bonds that connect mucin monomers are more
promising therapeutic approaches than alkalisation.
This article has supplementary material available from erj.ersjournals.com 
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Introduction
Airway surface liquid (ASL) protects the lung from airborne environmental irritants and infections. The
ASL consists of the periciliary layer (PCL) and mucus layer. The PCL is a grafted polymeric brush of
tethered mucins and other high-molecular-weight glycoproteins that provides: 1) lubrication for ciliary
beat and mucus layer transport, and 2) a size exclusion barrier [1]. The mucus layer is a viscoelastic fluid
comprised of over 1000 different proteins [2], including two secreted mucins, MUC5B and MUC5AC [3],
which give mucus its gel-like properties [3]. Collectively, the two layers of the ASL coordinate to trap and
clear inhaled pathogens from the lung via mucociliary transport (MCT).
It is well established that cystic fibrosis (CF) airway mucus has abnormal rheological properties, including
viscosities and elasticities orders of magnitude higher than normal mucus [1, 4–10]. There are currently
alternative hypotheses that describe the genesis of the pathologically viscoelastic mucus in CF. One
hypothesis predicts that impaired anion transport by the CF transmembrane regulator (CFTR), coupled to
persistent sodium absorption, reduces airway surface ion content [5]. The reduction of sodium (Na+) and
chloride (Cl−) ions on airway surfaces is coupled to reduced water flow to the airway lumen, dehydrating
the ASL, concentrating the mucus layer, and producing abnormal mucus viscoelastic properties and
osmotic pressures [1, 11]. A competing hypothesis posits that defective CFTR fails to transport
bicarbonate (HCO3
−) to the airway surface, acidifying the ASL. The resultant reduced mucus layer pH is
predicted to perturb the rheological properties of the mucus layer and impair clearance [12–14].
Mucus is a soft hydrogel composed of high-molecular-weight mucin polymers in an isotonic solvent.
The concentration and molecular weight of mucins in the mucus layer define the average distance
between adjacent mucin polymers in solution, i.e. the correlation length. The evidence that
concentration profoundly affects airway mucus biophysical properties has emerged from recent
measurements of mucus osmotic pressures and microbead rheology that employed probes with
diameters between 200 nm and 2 µm [1, 8, 11, 15]. The evidence that pH has effects on CF mucus gel
viscosity arose from fluorescence recovery after photobleaching (FRAP) mucus studies that employed
probes <10 nm in diameter [13]. Due to the length scale-dependent rheological properties of mucus
[16–18], it is impossible to compare mucus viscosity measurements directly with probes of differing
size. The 5-nm nanoscopic probes employed in FRAP protocols [13] diffuse in the solvent space
between mucin molecules, while the larger particles used in microbead rheology assays probe the
polymeric mucin network. We hypothesised that the mucus macroscopic rheological properties would
correlate better with MCT than nanoscopic measures.
Accordingly, studies were performed to measure the effects of mucus concentration versus pH on mucus
properties and transport at different length scales. Studies of the buffer capacity of mucus as a function of
concentration were first performed (see supplementary material). Next, pH- and mucus concentration-
dependent mucus viscosities were measured by FRAP. Biophysical measurements with length scales
relevant to mucus gels, e.g. traditional microrheology and microbead rheology with particles larger than
the mucus correlation lengths, were performed for comparison with FRAP measurements. Model porcine
gastric mucin (PGM), bovine submaxillary mucin (BSM), and human bronchial epithelial (HBE) mucus
from both normal and CF cultures were utilised for studies exploring: 1) pH ranges that exceeded those of
normal and CF airway mucus, and 2) mucus concentrations that spanned normal versus CF mucus. The
effects of changes in pH versus concentration on HBE MCT rates were directly compared. To test the
relevance of in vitro mucus to disease samples, the concentrations, pHs and viscoelastic properties of CF
sputum were measured and correlations analysed. Finally, the efficacy of three therapeutic strategies
designed to restore mucus viscoelastic properties, e.g. mucus hydration, alkalisation and chemical
reduction (i.e. mucolytics), were compared.
Methods
Mucus samples were prepared as described previously [19, 20], with buffer capacity measurements
performed as described elsewhere [21–23]. Spontaneous sputum samples were collected as detailed
previously [11, 24]. Detailed methods for the pooling of sputum samples are given in the supplementary
material. Mucus nanorheology was performed with FRAP assays [24], microrheology assays were
performed with particle-tracking microrheology of 1-µm diameter COOH-modified beads [8] and
cone-and-plate macroscopic rheology was performed as described previously [7, 25], ensuring that
measurements were taken in the linear viscoelastic regime (supplementary material). Osmotic
pressure, PCL height and MCT measurements were performed as described previously [1, 26]. HBE
cell cultures and mucus harvested from HBE cell cultures are considered nonhuman subjects under
the North Carolina Office of Research Ethics Biomedical Institutional Review Board protocol





Fluorescence recovery after photobleaching
Biophysical measurements of complex fluids such as mucus must be tailored to the relevant biological
questions (see supplementary material for more details). FRAP was measured using ∼5-nm dextran
molecules in HBE mucus and CF sputum of varying concentrations to determine the nanoscopic,
interstitial rheology of mucus (figure 1a). In both sample types, the diffusion of small molecules was
linearly dependent on the concentration of the mucus gels at a constant pH of 7.2 (figure 1b). ANCOVA
performed on the regression lines for τmucus/τsaline (which equates to the ratio of the viscosity of the
sample divide by the viscosity of saline) versus % solids in HBE mucus and CF sputum revealed that each
sample type exhibited significant (p<0.01) and similar (p=0.4, nonsignificant) correlations with mucus
concentration (n=3 per concentration). These data indicate that HBE mucus is a reliable surrogate for the
study of concentration-dependent FRAP-measured viscosity of CF sputum.
A second group of experiments examined the effect of pH on FRAP-measured viscosity in HBE mucus
and CF sputum at a constant concentration. Little evidence for a carbon dioxide (CO2) tension-dependent
effect on FRAP-measured viscosity was observed in HBE mucus (n=14) (figure 1c). In raw CF sputum
(9% solids), a trend towards an increase in FRAP recovery times (proxy for increased viscosity on the
nanometre length scale) was observed with acidification produced by 15% CO2 (p=0.19; n=7) (figure 1d).
To distinguish whether the pH effect on FRAP reflected an effect of the solvent or the mucin
polymer matrix, the sputum was filtered to remove the mucin polymer matrix (supplementary material).
The filtered sputum supernatant exhibited a significant (p=0.012; n=9) increase in FRAP recovery times at
15% CO2, similar in pattern to whole sputum (figure 1e). Thus, the 5-nm FRAP probe reported viscosity of
the solvent component of mucus, not of the polymeric gel. From the comparison of the composition of
HBE mucus and CF sputum, our results indicate that inflammatory proteins generated in vivo in CF
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FIGURE 1 Nanoscopic viscosity from fluorescence recovery after photobleaching (FRAP). a) Relevant
biophysical size scales in mucus, showing mucin polymers (black lines) with an average correlation length,
or mesh size, of 300–500 nm. The 1-µm diameter beads (blue) are larger than the correlation length. The
250-nm beads (red) are sufficiently near to the mesh size that their diffusive motion reflects both the
polymeric mucin network as well as the small proteins and solvent that permeate the intra-mucin space.
The 5-nm probes (purple) that are typically used in FRAP assays report the rheological properties of the
solvent/small-protein component of mucus. b) FRAP recovery times (τmucus/τsaline) for human bronchial
epithelial (HBE) mucus and cystic fibrosis (CF) sputum at various concentrations ranging from 2% to 17%
solids. c) FRAP recovery times (τmucus/τsaline) for HBE mucus at 5% and 15% CO2, resulting in a change in
pH from 7.2 to 6.6. Nonsignificant, p=0.6. d) FRAP recovery times (τmucus/τsaline) for whole, raw sputum at
5% and 15% CO2, resulting in a change in pH from 7.2 to 6.6. Nonsignificant, p=0.19. e) FRAP recovery
times (τmucus/τsaline) for the filtered, mucin-less solvent component of sputum at 5% and 15% CO2, resulting
in a change in pH from 7.2 to 6.6. *: p=0.012.
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Microbead rheology
Microbead rheology is a well-established technique capable of probing length scales of polymer networks
like mucus gels [18]. In PGM studies, a 2.5-fold increase in mucin concentration produced a 5-fold
reduction in bead mean squared displacement (MSD) at 1 s at each designated pH (figure 2a). In contrast,
changes in pH over a 100-fold range (pH 6–8) produced only a modest (1.5-fold) effect on MSD at 1 s
(figure 2a) at either mucin concentration. Parallel studies of the rheology of BSM showed similar
results (figure 2b). Notably, HBE mucus exhibited the greatest dependence on concentration and the least
on pH (figure 2c). The MSD of 1-μm beads embedded in normal HBE mucus exhibited a 10 times
reduction in MSD in response to a 2.5-fold increase in concentration compared with a 1.5 times reduction
in MSD in response to a 100-fold increase in proton concentration. A nearly identical result was observed
in CF HBE mucus (figure 2d). Two-way ANOVA analysis of the MSD at 1 s revealed a highly significant
relationship between microbead rheology with respect to concentration (p<0.01 for all samples; n=3 per
mucus type), while statistical significance was absent over the pH range investigated (p>0.05).
Macroscopic rheology
The macroscopic, or bulk, rheological properties of mucus are most often related to clearance of mucus
from the lung [27–29]. Both concentration and pH have been shown to affect the rheological properties of
mucus at these largest length scales [20, 30–32]. Figure 3 shows the relative effects of mucus concentration
versus pH on the complex viscosity of PGM, BSM and HBE mucus. PGM at 50 mg·mL−1 exhibited a
viscosity that was >10-fold higher than at 20 mg·mL−1. In contrast, PGM at 20 mg·mL−1 exhibited a
complex viscosity that did not vary systematically between pH 6 and 8 (figure 3a). BSM also exhibited
large concentration-dependent viscosities, e.g. 20 versus 50 mg·mL−1, with little pH dependence (figure 3b).
With respect to airway mucus, the complex viscosity of 4% solids HBE mucus was 6- to 10-fold
higher than 2% solids HBE mucus with again little systematic pH dependence (figure 3c). A similar
pattern was also found in CF HBE mucus (figure 3d). Two-way ANOVA revealed that concentration
significantly altered the macroscopic rheology of all mucus types (p<0.05), while pH showed no effect
(p>>0.05; n=3 per mucus type, concentration and pH). Thus, the result across all mucus samples was that
varying the concentration of mucus altered the complex viscosity dramatically, whereas variations in pH
10 20 mg·mL–1 pH 6
20 mg·mL–1 pH 7
20 mg·mL–1 pH 8
50 mg·mL–1 pH 6
50 mg·mL–1 pH 7
































































FIGURE 2 Microbead rheology. a, b) Mean squared displacement (MSD) curves for a) porcine gastric mucin
and b) bovine submaxillary mucin at 20 and 50 mg·mL−1 at pH 6, 7 and 8. c, d) MSD curves for c) human
bronchial epithelial (HBE) mucus and d) cystic fibrosis HBE mucus at 2% and 4% solids at pH 6, 7 and 8. In
each case, the results of two-way ANOVA showed significant dependence of MSD on concentration (p<<0.01)
and no significance on pH (p>0.05).
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did not. It is noteworthy that it is only at pH <5 that significant changes in the viscosity of 20 mg·mL−1
PGM mucus were observed, consistent with the previous findings of CELLI et al. [20] (supplementary
material).
Osmotic pressure and PCL height
The airway surface is lined by two apposing gel layers: 1) a mucus layer containing the secreted MUC5AC
and MUC5B mucins, and 2) a brush-like PCL containing tethered mucin (e.g. MUC1, MUC4 and
MUC16) and other glycoconjugates [1]. We have previously reported a HBE mucus concentration/osmotic
pressure-dependent reduction in PCL height and MCT [24]. We selected a mucus concentration for study
that produced a reduction in PCL height to test whether mucus osmotic pressure and PCL height
reduction were modified by pH. Changing mucus pH over a range from pH 8 to 6 did not alter osmotic
pressure of a concentrated (6.5% solids) mucus layer (p⩾0.14 between each pH by paired t-test) (figure 4a).
Consistent with the absence of a pH effect on osmotic pressure, PCL height was also not affected by
varying pH over this range (p⩾0.11 between each pH by paired t-test) (figure 4a). Note, PCL height with
normal mucus concentrations is ∼7 µm.
Mucociliary transport
MCT measures the integrated activities of cilia beat and mucus properties. Measurements of MCT in HBE
cultures identified that the baseline rate of MCT in these cultures over the initial portion of the
experiment was ∼60 µm·s−1. A representative experiment demonstrated that increasing the concentration
of CO2 from 5% to 15% in the luminal environment produced a decrease in the pH of the mucus layer
from 7.2 to 6.6 over 5 min (figure 4b). However, this reduction in pH did not produce a significant change
in mucus transport velocity. In contrast, when the concentration of mucus was raised from 2.8% to 12.6%
by removal of humidity from the environmental chamber, MCT ceased. The mean values for the effect of
pH versus concentration on MCT (figure 4c) demonstrated, as with micro- and macrorheology
measurements, mucus concentration (p<<0.05), not pH (p>>0.05; n=4–12), dominated MCT rates.
Relationships between mucus concentration, pH and viscoelastic properties in CF sputum
The concentration, pH and rheology of 11 CF sputum samples were measured (table 1). The average
concentration of these samples was 5.6±2.5%, the average pH was 7.1±0.42 and the average complex
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FIGURE 3 Macroscopic rheology of two concentrations of mucus at pH 6, 7 and 8. a, b) Complex viscosity (η*)
of a) porcine gastric mucin (PGM) and b) bovine submaxillary mucin (BSM) at 20 and 50 mg·mL−1. c, d)
Complex viscosity of c) human bronchial epithelial (HBE) mucus and d) cystic fibrosis (CF) HBE mucus at 2%
and 4% solids. Two-way ANOVA showed that the complex viscosities of PGM and normal and CF HBE mucus
were significantly dependent on concentration (p=0.031, p=0.038 and p=0.020, respectively), while BSM was of
borderline significance (p=0.05). In no case was there a significant correlation between pH and complex
viscosity (p=0.46 for PGM, p=0.77 for BSM and p=0.83 for HBE mucus). For reference, the viscosity of water is
∼0.001 Pa·s.
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viscosity (p=0.006) (figure 5a). In contrast, no correlation was observed between pH and complex viscosity
(p=0.42) (figure 5b). Thus, our data from cultured normal and CF HBE mucus appear to predict data
from CF sputum.
Testing therapeutic strategies to normalise CF sputum viscoelastic properties
To generate sufficient material for systematic studies of therapeutic agents, four sputum samples were
pooled and homogenised in the presence of protease inhibitors to blunt proteolysis. This pooled stock was
similar in concentration, pH and rheology to the sample group as a whole (supplementary material). The
concentration of the pooled samples (5.2%) mimicked the average concentration of all CF sputum samples
(5.6%). Aliquots of the pooled sputum were hydrated to 2.6% to mimic the effect of a mucus hydrator [33,
34], and then aliquots of sputum at both 2.6% and 5.2% concentrations were adjusted to pH 6, 7 and 8 to
test the effects of modulating pH on CF sputum.
Diluting (hydrating) mucus by a factor of 2 from 5.2% to 2.6% decreased the complex viscosity by a factor
of 8. In contrast, the effects of a 100-fold range in pH were small, i.e. ∼2-fold change in complex viscosity
(figure 5c). Importantly, increasing the pH of 5.2% CF sputum from pH 6 to 8 resulted in a complex
viscosity greater than the most acidic 2.6% concentration sputum sample (figure 5c). Thus, therapies
directed at hydration will likely produce more favourable changes in CF sputum viscosity than modulation
of pH.
Finally, the effect of reduction of mucin disulfide bonds was tested. We chose to reduce mucus with
dithiothreitol (DTT) rather than DNase as it has previously been shown to have a greater effect on sputum
rheology [35]. Normal HBE mucus was prepared to 5% solids to mimic CF sputum and reduced with 1
and 10 mM DTT versus PBS control. These data (figure 5d) showed that reduction of the disulfide bonds
















































































FIGURE 4 Effect of pH on osmotic pressure, periciliary layer (PCL) height and mucociliary transport (MCT). a) Effect of pH on mucus osmotic
pressure and PCL height of 6.5% solids mucus on human bronchial epithelial cell culture. Note that the PCL height is normally ∼7 µm with a
normal 2% solids (100 Pa) mucus layer apposed to it. b) Example trace of the effects of acidification (5% CO2, pH 7.2 to 15% CO2, pH 6.6)
compared with changes in mucus concentration (by dehumidification) on MCT rate during a single experiment. c) Summary of the MCT rates
comparing changes in concentration: 2.8% or 12.6% solids versus pH 6.6, 7.2 and 7.9.








Age years 28.5±9.6 (18–46)
FEV1 % pred 48.8±22.0 (24–90)
FVC L 2.7±1.0 (1.7–4.3)
FEF25–75% L·s−1 0.96±0.82 (0.3–2.7)
pH 7.1±0.42 (6.3–7.7)
Mucus concentration % solids 5.6±2.5 (2.3–10.6)
Complex viscosity η* Pa·s 2.5±1.5 (0.65–4.5)
Data are presented as n or mean±SD (range). FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; FEF25–75%: forced expiratory flow at 25–75% of FVC. Spirometry data were obtained for each
patient at the time of sample collection.
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properties of mucus than pH, i.e. exhibiting an effect similar to reducing concentration. This result was
mimicked by the reduction of 5% pooled CF sputum with 10 mM DTT (figure 5e).
Discussion
CF airways disease is characterised by highly viscous airway mucus that leads to mucus stasis,
inflammation, chronic infection and damage to airway walls. To test the current hypotheses that may
account for the increased viscosity of CF mucus, i.e. mucus acidification [13] versus concentration [1, 8,
11, 15], the relative effects of each variable were measured in model mucus systems (PGM and BSM), both
normal and CF HBE mucus, and CF sputum.
The pH ranges observed in human airway mucus [36, 37] are much narrower than in mucus in other
organs that are typically studied to describe pH effects on mucus properties, e.g. the endocervix [32] or
stomach [20]. The pH range of normal human airway mucus is pH ∼7.0–7.2. It is not clear how much
lower the pH of mucus in CF airways may be. CF airway epithelial cultures and CF animal models exhibit
a pH that may be ∼0.4 lower than normal airway mucus, i.e. ∼pH 6.8 [36, 38]. The lowest pH reported
for CF airway mucus emanated from studies of pH of mucopurulent material contained in excised CF
lungs and was pH 6.6 [37]. However, recent in vivo data have described little difference in large airway pH
in CF versus normal neonates [39]. Our strategy to address all possible CF mucus pH versus concentration
scenarios was to develop protocols that spanned: 1) pH ranges relevant to both CF (pH 6–8) and mucus
from other organs (pH 4–8), and 2) mucus concentrations from normal (2% solids) and CF subjects (>5%
solids) [11].
The mucus gel is composed of high-molecular-weight mucin polymers dissolved in an ASL solvent. In the
concentrations reported for normal and diseased mucus, the mucin polymers are in “overlap”
concentrations, meaning the mucin polymers interpenetrate. Mucin polymers in overlap conditions
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2.6% CF sputum 5.2% CF sputum
FIGURE 5 Cystic fibrosis (CF) sputum targets and candidate muco-corrective therapeutic strategies. a) Complex viscosity (η*) versus % solids for
CF sputum exhibited a significant relationship (n=11; p=0.006, r2=0.58). b) Complex viscosity versus pH for CF sputum samples exhibited no
significant correlation (p=0.42). c) Complex viscosity of pooled, homogenised CF sputum at 2.6% and 5.2% solids and pH 6, 7 and 8. Two-way
ANOVA indicated that complex viscosity was correlated to concentration (p=0.013), but not pH (p=0.10). d) Chemical reduction of normal human
bronchial epithelial mucus by dithiothreitol (DTT). The reduction of the complex viscosity of mucus by 10 mM DTT was found to be significantly
different than control (p=0.027). e) Chemical reduction of 5% pooled CF sputum shows a similar reduction when treated with 10 mM DTT
(p=0.008). For reference, the viscosity of water is ∼0.001 Pa·s.
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concentration. The correlation length ξ, i.e. mesh size produced by interpenetrating mucins, also scales to
a higher-order power of concentration (ξ∼kT/[concentration]3) and has been reported to be ∼100–500 nm
in normal mucus [15, 41]. The ASL solvent for mucus gels on airway surfaces has been characterised as an
isotonic liquid [42, 43].
The smallest nanoscopic rheological length scales of mucus scale to its solvent, which can be explored
by FRAP. Recent FRAP studies by TANG et al. [13], employing FITC-labelled 70-kDa dextran (radius
of gyration 6.6 nm [44]), demonstrated modest pH-dependent changes in the diffusion of these small
molecules in mucus. Our experiments with CF sputum, but not HBE mucus, are in agreement with
the FRAP data obtained by TANG et al. [13] in isolated CF piglet mucus (figures 3 and 5). We
interpret these data as indicating that the low-molecular-weight (potentially inflammatory) proteins
dissolved in the isotonic mucus solvent generated pH-dependent changes in viscosity that exceeded
that of water. Notably, the FRAP viscosity values measured in this study (0.001–0.003 Pa·s) and those
of TANG et al. [13] were orders of magnitude lower than the viscosity values of mucus (0.1–10 Pa·s) as
measured by macrorheology (see following paragraph and figure 3). The disparity in FRAP versus
macrorheology measurements, coupled with the mucin matrix–solvent separation studies (figure 2b),
indicates that the small-molecule FITC-labelled dextrans utilised in FRAP studies measured the
pH-sensitive properties of the low-viscosity mucus solvent and not the mucin structure/function that
dominates mucus clearance.
Microrheology protocols were performed with 1-µm beads, which probe mucus at length scales relevant to
the mucin mesh. Our microrheology studies of both PGM and BSM mucus showed a strong (geometric)
dependence of mucus complex viscosity on mucus concentration. In contrast, pH effects on PGM complex
viscosity were much smaller and only significant at pH <5 (supplementary material). These findings are in
agreement with the data of WANG et al. [32] in MUC5B-dominated endocervical mucus. Importantly, the
effects of pH on HBE mucus complex viscosity over pH ranges that span those of airway mucus in health
or disease (i.e. pH 6–8) were minimal compared with the effects of concentration on mucus harvested
from both normal and CF cultures.
Conventional cone-and-plate studies probe mucus rheology at macroscopic length scales. With this
approach, similar directional and quantitative data were observed as for microrheology (figure 3), i.e. pH
had little effect on complex viscosity over airway pH-relevant ranges. In contrast, strong concentration-
dependent relationships were observed, consistent with data of GEORGIADES et al. [31]. Although it has
typically been difficult to reconcile findings probing mucus rheological properties at different length scales,
our findings at all length scales are consistent with mucus concentration, not pH, dominating mucus
mesh-dependent rheological properties relevant to MCT.
Studies of CF sputum were performed for comparison with our mucus model systems. In raw sputum
from CF patients, like our model systems, a strong correlation between mucus concentration (p<0.05), but
not pH (p>0.3), and rheology was observed (figure 5a and b).
The water-drawing power of a polymer gel is described by its osmotic pressure. As with rheological
properties, osmotic pressures of polymer gels scale to higher-order powers of polymer (mucus)
concentration. Under normal conditions, the PCL is the more concentrated gel and is fully hydrated,
permitting the cilia to beat in a well-lubricated PCL environment. However, our data have shown that even
minor osmotic compression of the PCL by a modestly hyperconcentrated mucus layer (i.e. 4–5% solids)
produces sufficient compression of the cilia to slow mucus transport. Data presented in figure 4a
demonstrate that altering the pH across acidic versus alkaline ranges did not affect the osmotic properties
of the concentrated mucus layer. In contrast, modest mucus hyperconcentration produced the predicted
modest PCL compression (figure 4a).
To directly compare the effects of pH versus concentration on MCT rates, the effects of mucus pH versus
concentration on MCT were measured in HBE cultures (figure 4b and c). Consistent with the micro- and
macrorheology, MCT was governed by mucus concentration and not pH. These findings are consistent
with previous reports that showed MCT is dependent on mucus concentration, with MCT slowing at 4–5%
solids and ceasing at 8–10% solids [24, 45].
Therapeutic strategies to normalise CF mucus biophysical properties focused on concentration (hydration),
pH and disulfide bond reduction. Studies of CF sputum samples exposed to 2-fold variations in
concentration versus 100-fold variations in pH demonstrated that concentration, not pH, normalised
sputum complex viscosity. Chemical reduction of mucus by cleaving disulfide bonds with DTT decreased
the complex viscosity of mucus by similar fold values as hydration in both HBE mucus (figure 5d) and
pooled CF sputum (figure 5e). These data indicate that both hydration and chemical reduction may be
more effective muco-corrective treatments than alkalisation.
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The importance of concentration for the biophysical properties of mucus is rooted in the polymeric nature
of the mucin macromolecules that are the key gel-forming molecules in mucus. Increasing the
concentration of mucus and mucins in disease states [8, 11, 24] geometrically alters the viscoelastic and
osmotic properties of mucus [40], leading to a collapsed PCL [1], decreased mucociliary clearance [24],
reduced neutrophil penetration and bacteria killing [45], biofilm formation [15], and decreased pulmonary
function [24, 41, 46]. Collectively, increased mucus concentration can generate much of the
muco-obstructive pathophysiology typical of CF [8, 11, 24, 41].
The role of pH in airway disease states is less clear, with studies differing on the magnitude of the change
in pH across nasal models [47], newborn piglets [13], human cell cultures [36, 38, 39] and early in CF
patients in vivo [39]. Our data strongly argue that pH has little effect on the biophysical properties of
mucus relevant to basal mucus transport. It is possible that there is a role for acidification in bacterial
killing [48] that may add to failed mucus clearance in CF disease pathogenesis. We speculate, though, that
pathophysiologically relevant CF defects in airway pH regulation may be more important during gastric
aspiration. After aspiration, the pH of the airway surface is acutely acidified and takes longer to return to
baseline in CF than normal cultures [38]. Previous macro- and microscopic rheology studies found that a
reduction to pH 1–3 was required to produce the magnitude of mucus rheological abnormalities produced
by CF-relevant increases in mucus concentration [20, 30–32]. Thus, gastric aspiration may be combined
with increased mucus concentration to trigger early CF events and/or spread of CF lung disease.
Conclusions
Over the micrometre to millimetre length scales that probe the micro- and macrorheological properties of
mucin structure, mucus concentration, not pH, governed the biophysical properties of mucus important
for clearance from the lung. In contrast, FRAP studies that probe the solvent properties of the gel are not
relevant to the mucus mesh. Data from the larger length scale biophysical assays, but not FRAP, were
congruent with data from HBE MCT assays that also demonstrated the dominance of concentration in
controlling MCT. Mucus pH may have effects on antimicrobial killing in the CF lung. However, our
findings indicate that therapies designed to restore transport properties of mucus should focus on reducing
mucus concentration and/or mucolytic reduction rather than raising pH.
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